1. Generics Bulletin
  3. >>Strategy

Endo Wields The Axe Again As It Eyes $95m Annual Savings

Two US Manufacturing Sites To Close; Other Measures Taken

 
• By Dean Rudge

Hundreds more jobs are to go at Endo under further cost-cutting measures, including the closure of multiple sites serving the US-based player’s Generics business. Management discussed the issue on Endo’s third-quarter earnings call.

MoneyStack
Endo is eyeing up to $95m in pre-tax cash savings through the measures • Source: Shutterstock

Endo International will exit US generic manufacturing sites in Irvine, California and Chestnut Ridge, New York, as well as active pharmaceutical ingredient manufacturing and bioequivalence study sites in India, as part of broader cost-cutting efforts geared towards streamlining the company’s operations and increasing overall efficiency.

Tailored towards optimizing the US-based player’s Generics retail business cost structure, the site closures are to be conducted using a “phased approach that is

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Strategy

More from Business

‘I’ll Be Happy When We Have 40-Plus Assets’ – Sandoz Builds Up Biosimilars

 
• By Dave Wallace

With biosimilars playing an increasingly important role in Sandoz’s business, the firm’s first-quarter results call saw management lay out the latest key developments. Meanwhile, the company also addressed the issue of US tariffs, voicing optimism over both future developments as well as its ability to weather current measures.

Teva To Slash Thousands Of Jobs And Shut More Sites Under $700m Savings Plan

 
• By Dean Rudge

Teva’s plans to generate net savings of $700m by 2027 have been described by the firm as a journey and not a destination, with the suggestion that “this era of cost efficiency, harmonization, frugality will continue.”

Tetris Deal Falls Into Place For UK’s Aspire

 
• By Dave Wallace

Niche generics company Aspire Pharma has struck a deal to acquire a portfolio of products from fellow UK firm Tetris Pharma as it is wound up, paying Tetris parent Arecor £0.5m for UK distribution rights and inventory.